Enterprise Value
399.9M
Cash
26.38M
Avg Qtr Burn
-13.6M
Short % of Float
24.28%
Insider Ownership
1.58%
Institutional Own.
12.86%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OCU400 Details Retinitis Pigmentosa | Phase 3 Data readout | |
OCU400 Details Leber congenital amaurosis, Eye disease | Phase 3 Initiation | |
NeoCart® (Autologous chondrocyte-derived neocartilage) Details Articular cartilage defects in the knee | Phase 3 Initiation | |
OCU410 Details Geographic atrophy, Age-related macular degeneration | Phase 1/2 Update | |
OCU410ST Details Rare genetic disease, Stargardt disease | Phase 1/2 Update | |
COVAXIN (BBV152) Details COVID-19, Infectious disease | Failed Discontinued |